| ID | 10238 |
| Vaccine Name | BG505 mRNA |
| Disease Name | Acquired Immunodeficiency Syndrome (AIDS) |
| Disease Classification | Other |
| Virus Name | Human Immunodeficiency Virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Phase 1 |
| Manufacturer | National Institute of Allergy and Infectious Diseases |
| Year of Manufacturing | 2022 |
| Manufacturing Country | USA |
| Age | 18 - 55 years |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | BG505 MD39 mRNA |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | National Institutes of Health |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT05217641 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT05217641 |
| Additional Links | https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-three-mrna-hiv-vaccines
|